CIK: 0001917529 · Show all filings
Period: Q4 2023 (← Previous) (Next →)
Filing Date: Feb 9, 2024
Total Value ($000): $839,753 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | 5,858,262 | $149,151 | 17.8% | $58.25 | -69.3% | Common Stock | 501575104 |
| IRON | Disc Medicine, Inc. | 2,555,172 | $147,587 | 17.6% | $49.79 | +2.8% | Common Stock | 254604101 |
| DYN | Dyne Therapeutics, Inc. | 9,885,449 | $131,476 | 15.7% | $13.82 | -29.3% | Common Stock | 26818M108 |
| — | Third Harmonic Bio, Inc. | 10,907,859 | $119,659 | 14.2% | $18.97 | — | Common Stock | 88427A107 |
| DAWN | Day One Biopharmaceuticals, Inc. | 7,608,394 | $111,083 | 13.2% | $19.68 | -38.4% | Common Stock | 23954D109 |
| KRRO | Korro Bio, Inc. | 1,119,292 | $53,648 | 6.4% | $32.95 | 0.0% | Common Stock | 500946108 |
| — | Aerovate Therapeutics, Inc. | 2,039,249 | $46,148 | 5.5% | $11.88 | — | Common Stock | 008064107 |
| — | Vigil Neuroscience, Inc. | 5,836,874 | $19,729 | 2.3% | $7.03 | — | Common Stock | 92673K108 |
| REPL | Replimune Group, Inc. | 2,098,300 | $17,689 | 2.1% | $29.91 | -61.2% | Common Stock | 76029N106 |
| — | Generation Bio, Co. | 8,279,484 | $13,661 | 1.6% | $7.08 | — | Common Stock | 37148K100 |
| — | Ikena Oncology, Inc. | 5,018,178 | $9,886 | 1.2% | $12.54 | — | Common Stock | 45175G108 |
| — | Akero Therapeutics, Inc. | 359,251 | $8,389 | 1.0% | $21.15 | — | Common Stock | 00973Y108 |
| — | AvroBio, Inc. | 4,541,381 | $6,176 | 0.7% | $3.85 | — | Common Stock | 05455M100 |
| DNTH | Dianthus Therapeutics, Inc. | 236,979 | $2,465 | 0.3% | $12.62 | -12.4% | Common Stock | 252828108 |
| XLO | Xilio Therapeutics, Inc. | 2,759,344 | $1,518 | 0.2% | $17.03 | -91.7% | Common Stock | 98422T100 |
| SPRO | Spero Therapeutics, Inc. | 1,013,438 | $1,490 | 0.2% | $15.88 | -92.5% | Common Stock | 84833T103 |